Clinical Trial Update: PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating sintilimab plus capecitabine as adjuvant therapy for high-risk nasopharyngeal carcinoma; the trial status is not yet recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Tyvyt (Sintilimab)
• Xeloda (capecitabine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma (NPC) | Phase 3 | Status: NOT_YET_RECRUITING